Panwen Tian

机构：Sichuan University, West China Hospital of Sichuan University, Sichuan Cancer Hospital · ORCID：0000-0002-6313-3228

发表论文 160 篇 · 总被引 2278 次 · h-index 26

代表论文

• Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial (2025 · Journal of Thoracic Oncology · 被引 35)
• Pathogenesis and current status of the treatment of lung cancer associated with idiopathic pulmonary fibrosis (2025 · Respiratory Research · 被引 12)
• Ensartinib for advanced or metastatic non-small-cell lung cancer with MET exon 14 skipping mutations (EMBRACE): a multi-center, single-arm, phase 2 trial (2025 · EClinicalMedicine · 被引 9)
• Medical Thoracoscopy With vs Without Prior Artificial Pneumothorax for Patients With Minimal or Absent Pleural Effusion (2025 · CHEST Journal · 被引 6)
• Expert consensus on cancer treatment-related lung injury (2025 · Journal of Thoracic Disease · 被引 6)
• Phase 1 study of SHR-1826, a c-MET–directed antibody-drug-conjugate (ADC), in advanced solid tumors. (2025 · Journal of Clinical Oncology · 被引 5)